10.46243/jstj.2020.v5.i2.264 registered

_0 Flurbiprofen _0 is_0 non-steroidal_0 anti-inflammatory _0 drug_0 used_0 for_0 the_0 treatment_0 of_0 rheumatoid _0 arthritis_0 as_0 an_0 autoimmune _0 disease_0 that_0 causes_0 chronic_0 inflammation _0 of_0 the_0 joints._0 Flurbiprofen _0 is_0 a_0 potent_0 inhibitor_0 of_0 platelets_0 aggregation, _0 which_0 reduce_0 pain,_0 swelling_0 and_0 joint_0 stiffness._0 The_0 objective_0 of_0 this_0 study_0 was_0 to_0 formulate _0 and_0 evaluate_0 topical_0 flurbiprofen _0 emulgel_0 for_0 the_0 delivery_0 of_0 hydrophobic _0 drugs_0 to_0 systemic_0 circulation._0 In_0 present_0 work_0 flurbiprofen _0 emulgel_0 was_0 prepared_0 by_0 using_0 liquid_0 paraffin_0 (oil),_0 eucalyptus_0 oil_0 (penetration_0 enhancer) _0 and_0 xanthan_0 gum_0 used_0 as_0 gelling_0 agent._0 All_0 formulations _0 evaluated_0 for_0 homogeneity, _0 pH,_0 extrudability, _0 spreadability, _0 viscosity,_0 drug_0 content_0 and_0 drug_0 release._0 In-vitro_0 drug_0 release_0 of_0 emulgel_0 was_0 evaluated _0 by_0 using_0 diffusion_0 cell_0 containing _0 cellophane _0 membrane _0 with_0 phosphate _0 buffer_0 pH_0 7.4_0 as_0 the_0 receptor _0 medium._0 The_0 formulations _0 were_0 optimized _0 by_0 the_0 three_0 factors_0 and_0 two_0 levels_0 Box-Behnken _0 design_0 by_0 using_0 Design-Expert_0 software_0 (version_0 12)._0 Spreadability _0 of_0 F6_0 formulation _0 was_0 observed_0 (3.4_0 cm_0 in_0 diameter) _0 which_0 was_0 more_0 than_0 other_0 formulations. _0 Viscosity_0 of_0 F16_0 formulation _0 was_0 3067_0 cps._0 Percentage _0 Drug_0 content_0 of_0 F14_0 (98.61%) _0 has_0 shown_0 more_0 drug_0 content_0 as_0 compared _0 other_0 formulations. _0 In-vitro_0 diffusion_0 studies,_0 the_0 formulations _0 F5,_0 F6,_0 F13,_0 F14_0 and_0 F16_0 has_0 shown_0 more_0 than_0 80_0 %_0 of_0 drug_0 release_0 for_0 8_0 hrs._0